Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
RT GLP-3 / CAG
Batch #
N/A
Formula
C221H342N46O68
Mol Wt
4731 g/mol
CAS
2381089-83-2
Latest
ISO 17025
8× Testing
99.7%
Purity
VariantRT GLP-3 / CAG
COA ##13141
Labeled50mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.7%
✓
Net Peptide Content - 50mg
✓
Identity (HPLC) - RT GLP-3 / CAG
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
02
Cagrilintide at 2.4 mg for the treatment of obesity: a randomised, placebo-controlled and active-comparator-controlled phase 2 trial
03
Synergistic effects of semaglutide and cagrilintide on appetite, energy intake, body weight and glucose tolerance in lean and obese rats
04
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss
05
Pharmacokinetics, pharmacodynamics, and safety of cagrilintide, a novel long-acting amylin analogue
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
